Theodore Alan Huizenga - 16 Apr 2023 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Role
SVP, Chief Accounting Officer
Signature
/s/ Karah Parschauer, attorney-in-fact
Issuer symbol
RARE
Transactions as of
16 Apr 2023
Net transactions value
-$7,449
Form type
4
Filing time
18 Apr 2023, 16:57:55 UTC
Previous filing
03 Mar 2023
Next filing
10 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RARE Common Stock Tax liability $535 -14 -0.05% $38.20 27,701 16 Apr 2023 Direct F1
transaction RARE Common Stock Disposed to Issuer $6,914 -181 -0.65% $38.20 27,520 16 Apr 2023 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs").
F2 Shares were acquired upon the partial vesting of a previously reported RSU and were sold to permit the cash value of the awards to be credited to the deferred compensation plan account of the Reporting Person
F3 Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.